Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03958877 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
A Phase 3 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Biogen.
- Active
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT03958877 is a Phase 3 study of Multiple Sclerosis (Relapsing Remitting) that is active but no longer recruiting, run by Biogen. The registered enrollment target is 152 participants, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03958877, a Phase 3 study of Multiple Sclerosis (Relapsing Remitting), is active but no longer recruiting, sponsored by Biogen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the long-term safety of BIIB017 and further describe safety and the long-term multiple sclerosis (MS) outcomes after BIIB017 treatment in participants who completed the study treatment at Week 96 in Part 1 of the study.
Conditions Studied
Interventions
- DRUG BIIB017 (peginterferon beta-1a)
- DRUG Interferon beta type 1a
Study Locations (20)
Other
- MHATNP 'Sv.Naum', EAD - Sofia
- Children's Hospital Zagreb - Zagreb
- Clinical Hospital Center 'Sestre Milosrdnice' - Zagreb
- University Hospital Centre Zagreb - Zagreb
- Fakultni nemocnice Hradec Kralove - Hradec Králové
California
- UC San Diego Health - La Jolla
North Carolina
- UNC Hospitals - Chapel Hill
Virginia
- Meridian Clinical Research - Norfolk
Buenos Aires
- Hospital Italiano de Buenos Aires - Ciudad Autonoma Buenos Aires
Victoria
- Royal Children's Hospital - Parkville
East Flanders
- Universitair Ziekenhuis Ghent - Ghent
Wallonia
- Clinique CHC MontLégia - Liège
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2027-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03958877
The ClinicalTrials.gov registry entry for NCT03958877 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 557-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (73% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 2 interventions - of which BIIB017 (peginterferon beta-1a) is the first listed.
NCT03958877 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03958877 about?
NCT03958877 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis". This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants with RRMS in Part 1. In Part 2, the study will evaluate the...
What is the current status of trial NCT03958877?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2019-10-18. Estimated completion is 2027-05-20.
What conditions does trial NCT03958877 study?
This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).
What interventions are being tested in trial NCT03958877?
The interventions under investigation include: BIIB017 (peginterferon beta-1a) (DRUG), Interferon beta type 1a (DRUG).
Who is sponsoring clinical trial NCT03958877?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03958877 being conducted?
This trial has 20 study locations across California, North Carolina, Virginia, Buenos Aires, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis (Relapsing Remitting)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
COMPLETED · Phase 3
-
ACTH for Fatigue in Multiple Sclerosis Patients
COMPLETED · Phase 3
-
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
COMPLETED · Phase 3
-
Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.